Posted on 17/11/2009 in Pharmaceutical Company Product News
Abbott has revealed that a trial into its fully bioabsorbable drug eluting coronary stent produced a positive outcome.
The results, which were collated over three years across 30 patients, found that the stent successfully treated coronary artery disease and was effectively absorbed into the walls of the patients' arteries.
Those treated within the first phase of the trial experienced no blood clots and no new major adverse cardiac events between six months and three years.
Principal investigator of the trial Patrick Serruys stated: "Abbott's bioabsorbable stent has the potential to be a major breakthrough for coronary artery disease patients. The data show that patients continue to do well three years after treatment."
Meanwhile, Abbott also announced this week that it plans to acquire the rights to a product portfolio from PanGenetics BV.
This includes the company's PG110 fully-humanised antibody to Nerve Growth Factor and will expand Abbott's pain care expertise.
